Matches in Wikidata for { <http://www.wikidata.org/entity/Q92966498> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q92966498 description "artículu científicu espublizáu en mayu de 2019" @default.
- Q92966498 description "scientific article published on 16 May 2019" @default.
- Q92966498 description "wetenschappelijk artikel" @default.
- Q92966498 description "наукова стаття, опублікована 16 травня 2019" @default.
- Q92966498 name "Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β2-agonists in South Korea" @default.
- Q92966498 name "Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β2-agonists in South Korea" @default.
- Q92966498 type Item @default.
- Q92966498 label "Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β2-agonists in South Korea" @default.
- Q92966498 label "Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β2-agonists in South Korea" @default.
- Q92966498 prefLabel "Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β2-agonists in South Korea" @default.
- Q92966498 prefLabel "Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β2-agonists in South Korea" @default.
- Q92966498 P1433 Q92966498-A42D4F6D-5A07-48E2-AF44-5ED641937C78 @default.
- Q92966498 P1476 Q92966498-8B211824-11B5-4F3A-AC5B-97E8169E8567 @default.
- Q92966498 P2093 Q92966498-03D7151F-6DB6-4E51-867C-A8032E5B298F @default.
- Q92966498 P2093 Q92966498-31D96ADC-5D21-40ED-AD6D-FC2BD2793D97 @default.
- Q92966498 P2093 Q92966498-67C46857-B15E-4802-BB04-1671120B1406 @default.
- Q92966498 P2093 Q92966498-BB618835-F376-4D19-BDE0-129F5C43C228 @default.
- Q92966498 P304 Q92966498-2E5DAF03-9EBB-453D-A620-B90BD3FC9A82 @default.
- Q92966498 P31 Q92966498-8F00EE57-022E-4DB4-BE02-D26C326307A8 @default.
- Q92966498 P356 Q92966498-8D8A7A63-AA8B-4E91-8CB6-3E4632D2B129 @default.
- Q92966498 P433 Q92966498-522EB21F-7DD4-43D9-8A9E-69E8A76ADF8D @default.
- Q92966498 P478 Q92966498-0C5CF118-36CF-4A02-A1B2-8C23DEF108DD @default.
- Q92966498 P577 Q92966498-13AF6260-B6B0-4ED2-9B40-4F23684424F8 @default.
- Q92966498 P698 Q92966498-D5A3DE6B-6629-483C-9B27-6ABCF265FE82 @default.
- Q92966498 P921 Q92966498-C9A70CA0-98A4-469E-BA80-41E46F6DA2DC @default.
- Q92966498 P356 03007995.2019.1605159 @default.
- Q92966498 P698 30964365 @default.
- Q92966498 P1433 Q5195063 @default.
- Q92966498 P1476 "Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β2-agonists in South Korea" @default.
- Q92966498 P2093 "Hae Sun Suh" @default.
- Q92966498 P2093 "Hyungtae Kim" @default.
- Q92966498 P2093 "Siin Kim" @default.
- Q92966498 P2093 "Sola Han" @default.
- Q92966498 P304 "1597-1605" @default.
- Q92966498 P31 Q13442814 @default.
- Q92966498 P356 "10.1080/03007995.2019.1605159" @default.
- Q92966498 P433 "9" @default.
- Q92966498 P478 "35" @default.
- Q92966498 P577 "2019-05-16T00:00:00Z" @default.
- Q92966498 P698 "30964365" @default.
- Q92966498 P921 Q884 @default.